NCT02492763: A reported trial by Merck Sharp & Dohme LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02492763 |
|---|---|
| Title | A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects With Type 2 Diabetes Mellitus |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 27, 2015 |
| Completion date | April 18, 2017 |
| Required reporting date | April 18, 2018, midnight |
| Actual reporting date | Jan. 18, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |